Skip to main content
OpenTrials

Clinical trial condition

Demyelinating Diseases

Explore clinical trials studying Demyelinating Diseases. Study availability and eligibility vary by location and protocol.

2,934 public trials 459 recruiting studies
Refine in advanced search Browse all conditions

Demyelinating Diseases trial results

Completed

A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT00882999

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +11 more
Locations
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Phoenix, Arizona, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Tucson, Arizona, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Fullerton, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Denver, Colorado, United States
View all 63 locations
View Trial Details
Completed

Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya

NCT02137707

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • University of British Columbia Vancouver, British Columbia, Canada
  • Dalhousie University Multiple Sclerosis Research Unit Halifax, Nova Scotia, Canada
  • Ottawa General Hospital Ottawa, Ontario, Canada
  • Clinique Neuro Rive-Sud Greenfield Park, Quebec, Canada
View Trial Details
Completed

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis

NCT01051349

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Brno, Czechia
  • Research Site Brno, Czechia
  • Research Site Hradec Králové, Czechia
  • Research Site Prague, Czechia
View all 65 locations
View Trial Details
Completed

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis

NCT01585766

Conditions
Actinomycetales Infections, Autoimmune Diseases, Autoimmune Diseases of the Nervous System, +12 more
Locations
  • Research Site Scottsdale, Arizona, United States
  • Research Site Long Beach, California, United States
  • Research Site Sacramento, California, United States
  • Research Site Denver, Colorado, United States
View all 16 locations
View Trial Details

Related conditions